# Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma

> **NCT02843386** · PHASE3 · COMPLETED · sponsor: **Institut Curie** · enrollment: 302 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Adjuvant chemotherapy by Fotemustin
- **OTHER:** Intensive surveillance

## Key facts

- **NCT ID:** NCT02843386
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-23
- **Primary completion:** 2020-06-12
- **Final completion:** 2020-06-12
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2022-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843386, "Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02843386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*